Celgene Corporation

Otsuka America Pharmaceutical, Inc.

Neurovance, Inc.

Teva Pharmaceutical Industries Limited

Noven Therapeutics, LLC

David Alan Engers

Valeriya N Smolenskaya

Yonglai Yang

Fred J Fleitz

Anthony Alexander McKinney

Walter Piskorski

Venkat Kusukuntla

Franklin Bymaster

Jason A Hanko

Eric J Hagen

Jeffrey Stults

Stephan D Parent

Travis Houston

Bruce Charles Friedman

Keith Lorimer

Valeriya Smolenskaya

Anthony Alexander Mckinney

Viktor Tzatchev Peykov

Jason Hanko

Neil Lawrence Darling

Nicholas Vrolijk

Eric Hagen

Willard Rodney Foss

Vijay Harishchandra Naringrekar

Jeffrey Scott Stults

The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.

Crystalline compounds

The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.

Romidepsin solid forms and uses thereof

The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60&#xb0; C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient. Methods for the treatment using paroxetine mesylate in the form of a solid dispersion according to the invention are also disclosed.

Solid dispersions of amorphous paroxetine mesylate

The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.

Dispersions of rasagiline citrate

Growing community of inventors

West Lafayette, IN, United States of America

David Alan Engers